A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Trial Profile

A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisolone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2020.
    • 28 Jul 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top